Labiotech.eu

News and Trends 7 Sep 2022

OncoResponse and Regeneron to evaluate drug combo for patients with advanced cancer

OncoResponse, a clinical-stage biotech company advancing immunotherapies derived from the immune systems of elite cancer responders, has announced a clinical supply agreement with Regeneron for PD-1 inhibitor Libtayo (cemiplimab). The supply agreement with Regeneron will support the evaluation of Libtayo in combination with OR2805, a fully human monoclonal antibody identified from an elite cancer responder […]

September 7, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 7 Sep 2022

Benchling launches solution to boost mRNA and RNA therapeutics development

Benchling has launched what it says is the industry’s first full set of capabilities for designing, modeling, and studying natural and chemically modified RNA in a single solution. As the biopharma industry increases its focus on developing RNA therapeutics, Benchling said its new RNA solution is the first purpose-built offering on the market to help […]

September 7, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 7 Sep 2022

Alzinova announces new positive safety review for Alzheimer’s study

Alzinova AB says a second external safety review has been carried out of its clinical phase 1b study. This resulted in a positive assessment to continue the study as planned. Behind the review is an independent expert group, Data and Safety Monitoring Board (DSMB), which continuously reviews the study. Based on the patients included in […]

September 7, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 7 Sep 2022

Lytix Biopharma expanding advanced melanoma study to Europe

Lytix Biopharma, a Norwegian immuno-oncology company, has received regulatory approval from European authorities to start its ATLAS-IT-05 study in three European countries. ATLAS-IT-05 is a phase II combination study evaluating LTX-315 and pembrolizumab in patients with advanced melanoma. The study was initiated at MD Anderson Cancer Center in 2021 and is currently ongoing in the […]

September 7, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 7 Sep 2022

Ionis presents positive study results at International Symposium on amyloidosis

Ionis Pharmaceuticals, Inc. has presented positive results from a planned 35-week interim analysis of the phase 3 NEURO-TTRansform study of Ionis and AstraZeneca’s eplontersen in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN). In the study, eplontersen demonstrated a statistically significant and clinically meaningful change from baseline for its co-primary and secondary efficacy endpoints compared to […]

September 7, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 7 Sep 2022

Could COVID vaccine boosters become obsolete?

A team of researchers at Tel Aviv University in Israel has demonstrated that antibodies isolated from the immune system of recovered COVID-19 patients are effective in neutralizing all known strains of the virus, including the Delta and the Omicron variants. According to the researchers, this discovery may eliminate the need for repeated booster vaccinations and […]

September 7, 2022 - 5 minutesmins - By Jim Cornall

News and Trends 7 Sep 2022

TikoMed drug inhibits infection of human cells by dengue, zika and yellow fever viruses

TikoMed has announced the inclusion in bioRxiv of an in vitro study examining the ability of the company’s lead drug candidate ILB to inhibit infection of human cells by four serotypes of dengue virus (DENV1-4), two strains of zika virus (African and Asian) and yellow fever virus (vaccine strain YF17D) assessed by immunofluorescence of viral […]

September 7, 2022 - 2 minutesmins - By Jim Cornall

Opinion 6 Sep 2022

Meeting tech transfer challenges when manufacturing new biopharmaceuticals

With increasingly complex therapeutics arriving almost monthly, efficient technology transfer between biopharma and manufacturers is more important than ever. Ken Forman, senior director of product strategy at IDBS, explains how good digital strategies can avoid common pitfalls in the tech transfer process. Biopharmaceutical lifecycle management (BPLM) is the key to delivering novel therapies and lifesaving […]

September 6, 2022 - 7 minutesmins - By External Contributor

News and Trends 6 Sep 2022

Lonza and Touchlight collaboration will expands customer’s access to DNA

Manufacturing partner, Lonza, has today (September 6) announced a collaboration with Touchlight, a biotech company that works with enzymatic DNA production enabling genetic medicine. Through this collaboration, Lonza says it will have the ability to expand it end-to-end offering for mRNA manufacturing with an additional source of DNA raw material. This material comes from Touchlight’s […]

September 6, 2022 - 2 minutesmins - By Liza Laws

News and Trends 6 Sep 2022

More companies enter BioInnovation Institute Venture Lab program

Nine ventures and two projects have become the latest addition to The BioInnovation Institute’s (BII) Venture Lab acceleration program for early-stage companies. BioInnovation Institute is an international commercial non-profit foundation based in Denmark, which incubates and accelerates life science research. The cohort consists of nine ventures plus two corporate-sponsored innovation projects from Novo Nordisk – […]

September 6, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 6 Sep 2022

Finnish researchers use machine learning to unlock clinical cancer samples’ genomic code

A new paper from the University of Helsinki, published in Nature Communications, suggests a method for accurately analyzing genomics data in archival cancer biopsies. The tool uses machine learning methods to correct damaged DNA and unveil the true mutation processes in tumor samples. This helps to unlock medicine values in millions of archival cancer samples. […]

September 6, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 6 Sep 2022

IRLAB’s partner Ipsen starts mesdopetam clinical studies

IRLAB Therapeutics AB, a clinical-stage biopharmaceutical company discovering and developing novel treatments for the most troublesome symptoms of Parkinson’s disease, says its partner, Ipsen, has initiated clinical studies with drug candidate mesdopetam in accordance with its development plan. These are standard clinical pharmacokinetic studies that will run in parallel to the phase IIb study with […]

September 6, 2022 - 3 minutesmins - By Jim Cornall

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

OncoResponse and Regeneron to evaluate drug combo for patients with advanced cancer

Benchling launches solution to boost mRNA and RNA therapeutics development

Alzinova announces new positive safety review for Alzheimer’s study

Lytix Biopharma expanding advanced melanoma study to Europe

Ionis presents positive study results at International Symposium on amyloidosis

Could COVID vaccine boosters become obsolete?

TikoMed drug inhibits infection of human cells by dengue, zika and yellow fever viruses

Meeting tech transfer challenges when manufacturing new biopharmaceuticals

Lonza and Touchlight collaboration will expands customer’s access to DNA

More companies enter BioInnovation Institute Venture Lab program

Finnish researchers use machine learning to unlock clinical cancer samples’ genomic code

IRLAB’s partner Ipsen starts mesdopetam clinical studies

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!